Frankel, Arthur E.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 709

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die

Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., & Thorburn, A. (2009) · Cell Death & Differentiation

Autophagy in Disease and TherapyCell death mechanisms and regulation

Cited by 268

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 188